EDP‐323, a First‐In‐Class, Once‐Daily, Oral L‐Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy Adults

Documenti analoghi

• First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects
  di: Tomoki Kojima, et al.
  Pubblicazione: (2026)
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study
  di: Avner Sandhu, et al.
  Pubblicazione: (2025)
• Evaluation of Drug–Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants
  di: Alison Luckey, et al.
  Pubblicazione: (2026)
• Assessment of QT Interval Prolongation Using Concentration– QT Modeling for Iptacopan, an Oral Complement Factor B Inhibitor, in Healthy Individuals
  di: Noemi Kaetterer, et al.
  Pubblicazione: (2025)
• First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults
  di: Marcus May, et al.
  Pubblicazione: (2025)